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Induction of an effective tumor immunity is a complex process that includes the
appropriate presentation of the tumor antigens, activation of specific T cells, and the
elimination of malignant cells. Potent and efficient T cell activation is dependent on
multiple factors, such as timely expression of co-stimulatory molecules, the differentiation
state of professional antigen presenting cells (e.g., dendritic cells; DCs), the functionality
of the antigen processing and presentation machinery (APPM), and the repertoire of
HLA class I and II-bound peptides (termed immunopeptidome) presented to T cells.
So far, how molecular perturbations underlying DCs maturation and differentiation affect
the in vivo cross-presented HLA class I and II immunopeptidomes is largely unknown.
Yet, this knowledge is crucial for further development of DC-based immunotherapy
approaches. We applied a state-of-the-art sensitive MS-based immunopeptidomics
approach to characterize the naturally presented HLA-I and -II immunopeptidomes eluted
from autologous immune cells having distinct functional and biological states including
CD14+ monocytes, immature DC (ImmDC) and mature DC (MaDC) monocyte-derived
DCs and naive or activated T and B cells. We revealed a presentation of significantly
longer HLA peptides upon activation that is HLA allotype specific. This was apparent in
the self-peptidome upon cell activation and in the context of presentation of exogenously
loaded antigens, suggesting that peptide length is an important feature with potential
implications on the rational design of anti-cancer vaccines.
Keywords: antigen processing and presentation, dendritic cells, immunopeptidomics, mass spectrometry, cancer
antigens
INTRODUCTION
The primary aim of the adaptive immune system is to provide highly specific response against
“non-self ” antigens and generate memory to counter similar insults in the future (1). Professional
antigen presenting cells (APCs) have the key role in presenting antigens in the context of the
Human Leukocyte Antigen (HLA) complex molecules that are recognized by T cells via the T cell
receptors (TCR). Intracellular degradation of proteins generates short peptides that are transferred
into the Endoplasmic reticulum where they can be presented in complex with the HLA class I
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(HLA-I) molecules. HLA-I restricted presentation alerts the
immune system about intracellular pathogens or malignant
transformation by displaying targets for CD8+ T cells. HLA
class II (HLA-II) complexes present antigens to CD4+ T cells.
HLA-II complexes are loaded with peptides that are mainly
degradation products of cellular proteins that reached the
endosome-lysosome compartments (2). Dendritic cells (DCs) are
uniquely equipped for taking up exogenous antigens, such as
those released from dying cells in the tumor microenvironment.
Exogenous antigens can then be processed within the DCs and
presented on HLA-II complexes and in a process known as
cross-presentation, they can be presented also on HLA class I
molecules (3, 4). Due to these unique properties, DCs are the
most potent primers of naïve T cells and they are essentially the
master regulators of immune system (5).
Because DCs play a key role in boosting endogenous immune
responses, numerous DC-based anti-cancer immunotherapies
have been tested in clinical trials demonstrating that ex vivo-
generated DCs loaded with specific tumor antigens, including
mutated neoantigens, or tumor lysates, are promising therapeutic
approaches (6, 7). However, so far, they have not been translated
into meaningful therapeutics (8). Induction of an effective tumor
immunity is a complex process that includes the appropriate
presentation of the tumor antigens, activation of specific T
cells, and the elimination of malignant cells (9). Tumor specific
antigens are mostly self-antigens typically overexpressed or
abnormally expressed in tumors. Due to the tolerance of T cells to
self-antigens, much attention has been driven toward strategies
to maximize the immune-stimulatory features of DCs, with the
hope that these would break this tolerance (10). Importantly,
potent and efficient T cell activation mediated by DCs is
dependent on the DCs maturation and differentiation state, on
timely expression of co-stimulatory molecules, the functionality
of the antigen processing and presentation machinery (APPM)
and ultimately, on the repertoire of HLA class I and II-bound
peptides (termed immunopeptidome) presented to T cells (11).
Several studies extensively described the cellular processes and
time-dependent regulation of gene expression (12–17) mediating
DCs differentiation and maturation, among them the release
of cytokine and growth factors (18, 19), and the expression
of co-stimulatory molecules (20) that eventually lead to their
ability to process antigens and stimulate T cells (21, 22). The
repertoire of the presented class I and II immunopeptidomes
are constantly modulated by source protein expression levels and
by several enzymes, chaperones, and transporters that comprise
the APPM (23). So far, how molecular perturbations underlying
DCs maturation and differentiation affect the in vivo cross-
presented HLA class I and II immunopeptidomes is largely
unknown. Furthermore, the similarity between the repertoire
of HLA ligands presented on DCs and on tumor cells, and
more specifically, of the epitopes presented from exogenously
loaded tumor antigens, has not been thoroughly investigated.
Yet, this knowledge is crucial to further develop DC-based
immunotherapy approaches.
Presently, mass spectrometry (MS) is the only unbiased
methodology that facilitates a comprehensive interrogation
of the naturally presented HLA-bound repertoires (24).
Technical limitations related to sensitivity, low throughput
and reproducibility of existing methodologies posed a
limit to a detailed assessment of the in vivo DCs-derived
immunopeptidomes, due to very low starting cell amounts. In
order to overcome these limitations, we recently developed an
extraction pipeline for immunopeptidomics, which achieved
greater sensitivity and reproducibility (23, 25). In this work,
we attempted to deepen our understanding on how molecular
perturbations underlying DC differentiation and maturation
could affect the in vivo (cross-) presented HLA-I and -II
immunopeptidomes. We focused on the analysis of autologous
systems having distinct cell functional and biological states
including CD14+ monocytes, immature DC (ImmDC), and
mature DC (MaDC) monocyte-derived DCs, naive or activated
T and B cells. We performed shotgun proteomics comparative
analyses in combination with flow cytometry in order to achieve
a global view on protein expression profiles, signaling pathways,
and modulation of the APPM components. Uniquely to our
work, we interrogated the functionality of the APPM by applying
MS-based immunopeptidomics approach to characterize the
naturally presented HLA-I and -II immunopeptidomes eluted
from the different cell types. Upon activation and in the context
of direct presentation and cross-presentation of exogenously
loaded antigens, cells present significantly longer HLA peptides
in HLA allotype specific manner. We discuss the importance of
this feature and the potential clinical implications related to the
rational design of anti-cancer vaccines.
MATERIALS AND METHODS
Human Immune Cell Generation and
Activation
Fresh peripheral blood mononuclear cells (PBMCs) were
obtained from healthy donors and informed consent of
the participants was obtained following requirements of the
institutional review board (Ethics Commission, CHUV). The
translational research has been approved by the CHUV ethics
committee (protocols 2017-00305). High-resolution 4-digit
HLA-I and HLA-II typing was performed for all donors at the
Laboratory of Diagnostics, Service of Immunology and Allergy,
CHUV, Lausanne, and provided in Supplementary Table 1.
PBMCs were separated from red blood cells (RBCs) by
density gradient centrifugation with Lymphoprep and SepMate
centrifuge tubes (STEMCELL Technologies SARL) by following
manufacturer instructions. Monocytes CD14+, CD4+,CD8+,
and CD19+ cells were separately isolated by MACS LS
Columns for magnetic cell isolation with MicroBeads Human
CD14+, CD4+, CD8+, and CD19+ kits, respectively (all
from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany),
following manufacturer instructions. Purified CD14+ monocytes
were either washed twice with ice cold PBS and stored
as dry cell pellets at −20◦C until use, or cultured at 1e6
cells/ml in RPMI 1640 GlutaMAX medium, with addition of
1% Penicillin/Streptomycin Solution and 10% heat-inactivated
FBS. For differentiation to ImmDCs, similarly to a previously
published protocol (26), CD14+ monocytes were cultured in
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the presence of recombinant research grade human granulocyte-
macrophage colony stimulating factor (GM-CSF; 500 IU/ml,
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and
interleukin-4 (IL-4; 250 IU/ml, Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany). After 2–3 days, 10% of medium was
added together with fresh cytokines (GM-CSF; 500 IU/ml) and
interleukin-4 (IL-4; 250 IU/ml). DCs were matured for 24 h with
LPS (60 EU/ ml) and IFNγ (2,000 IU/ml, Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany).
For experiment comparing ImmDC and MaDC, at 6-day
culture period, the growth medium of ImmDCs was doubled
(5e5 cells/ ml), fresh GM-CSF and IL-4 were added (respectively,
500 and 250 IU/ml) for both cell types. For the comparison
of DCs loaded with synthetic peptides, ImmDC DCs at 6-day
were loaded with seven synthetic long peptides at 10 ug/ml final
concentration each. ImmDCs were either kept in this culture
condition for extra 24 h, or maintained in medium supplemented
with LPS (60 EU/ ml) and IFNγ (2,000 IU/ml, Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) for 24 h to mature into
MaDC. ImmDC and MaDC DCs were collected on the same day
by centrifugation at 1,200 rpm for 5min, washed twice with ice
cold PBS and stored as dry cell pellets at−20◦C until use.
Similarly to a previous report (27), purified CD8+ and CD4+
cells were either washed twice with ice cold PBS and stored
as dry cell pellets at −20◦C until use, or cultured at 1e6
cells/ml in RPMI 1640 GlutaMAX medium, with addition of
1% Penicillin/Streptomycin Solution and 10% heat-inactivated
FBS. For CD8+ and CD4+ activation, PMA (10 ng/ml) and
Ionomycin (1µg/ml) were added to the medium for 48 h.
Cells were harvested, washed twice with ice cold PBS and
stored as dry cell pellets at −20◦C until use. Purified CD19+
cells were either washed twice with ice cold PBS and stored
as dry cell pellets at −20◦C until use, or cultured at 2e6
cells/ml in Iscove’s modified Dulbecco medium (IMDM, Life
Technologies, Carlsbad, CA, United States), with addition of 1%
Penicillin/Streptomycin Solution and 10% heat-inactivated AB
human serum. For CD19+ activation, IL-4 (2 ng/ml, Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) and CD40L-Tri
(1µg/ml, Adipogen Life Science, Epalinges, Switzerland) were
added to the medium for 48 h (28). Cells were harvested, washed
twice with ice cold PBS and stored as dry cell pellets at −20◦C
until use.
Flow Cytometry Analysis
Cells were phenotyped by Flow Cytometry, as indicated in
the results section. Briefly, cell suspensions were incubated
for 10min at room temperature with human Fc blocking
solution (BD Biosciences) to block unspecific Fc receptor
binding and were subsequently stained at 4◦C for 30min with
the following antibody mixes, depending on the cell type:
DCs were stained with anti-human CD11c-BV711 (3.9), HLA-
A,B,C-PerCP-Cy5.5 (W6/32), HLA-DR,DP,DQ- Alexa Fluor 700
(Tu39), PD-L1-BV421 (29E.2A3), PD-L2 (24F.10C12), CD40-
BV605 (5C3) purchased from BioLegend, CD14-V500 (M5E2),
CD80-PE-Cy7 (l307.4), CD86- Alexa Fluor 700 (2331) from BD
Biosciences, and CD83-FITC (HIB15a) from Beckman Coulter.
DAPI (Sigma) was added in all samples right before acquisition
to determine cell viability. The following gating strategy was
employed to identify them: first, viability was determined with
DAPI staining and DAPI+ cells were excluded. Cells were then
gated based on size and granularity (FSC/SSC) and doublets
were excluded. DCs were identified by the expression of marker
CD11c and lack of CD14 expression. CD19+ B cells were
stained with anti-human CD19-BV711 (HIB19), HLA-A,B,C-
PerCP-Cy5.5 (W6/32), HLA-DR,DP,DQ-Alexa Fluor 700 (Tu39)
from BioLegend, CD80-PE-Cy7 (l307.4), CD86-Alexa Fluor 700
(2331) from BD Biosciences and CD83-FITC (HIB15a) from
Beckman Coulter. Same gating strategy was used for viability,
size, and doublet exclusion as with DCs and B cells were
selected based on CD19 positivity. Last, CD4+ and CD8+ T
cells were stained with anti-human: CD8-PE (T8), HLA-A,B,C-
PerCP-Cy5.5 (W6/32), HLA-DR,DP,DQ-FITC (Tu39), PD-1-
BV421 (EH12.2H7), CD38-PE-Cy7 (HIT2), CD25-APC (BC96),
CCR7-APC-Cy7 (G043H7), CD69-Alexa Fluor 700 (FN50) from
BioLegend, CD4-BV605 (RPA-T4) and CD137-BV711 (4B4-1)
from BD Biosciences and CD54RA-ECD (2H4) from Beckman
Coulter. Similar gating strategies were followed as described
above, and T cells were identified based on expression of CD4
and CD8, respectively. Cells were acquired on a 5-laser LSR-
SORP (BD Biosciences) and results were analyzed with FlowJo
v.10 (TreeStar, California).
Scheme of Synthetic Peptides Selection
for Exogenous Dendritic Cell Loading
An in-house built database, comprising shotgun proteomics
and HLA-I and HLA-II immunopeptidomics data from tumor
tissues, cancer cell lines and CD14+, ImmDC, and MaDC was
mined to select tumor antigens not expressed and/or HLA-
presented in DCs (29). HLA-I and -II-bound peptides identified
by MS were mapped on the sequence of the source tumor
antigens and “hotspots” of antigen presentation were identified.
Selected “hotspots” sequences (25 to 40 mers) were further tested
with predictions for binding to the common HLA-A and -B
supertype representatives. Seven long peptides were selected for
synthesis and exogenous loading to ImmDC and MaDC.
Long Synthetic Peptides Sequences
WLGVSRQLRTKAWNRQLYPEWTEAQRLDCWR (peptide
from PMEL from position 32 to 61 of the protein sequence,
named “PMEL32”), VLGGPVSGLSIGTGRAMLGTHTME
VTVYHRRGSR (peptide from PMEL from position 155 to
195 of the protein sequence, named “PMEL155”), SSAFTITD
QVPFSVSVSQLRALDGGNKHFLRNQPL (peptide from PMEL
from position 201 to 234 of the protein sequence, named
“PMEL201”), YLEYRQVPGSNPARYEFLWGPRALAETSYV
(peptide from MAGEA4 from position 256 to 285 of the
protein sequence, named “MAGEA4”), DSKVSLQEKNCEPVVP
NAPPAYEKLSAEQSPPPYSP (peptide from MLANA from
position 83 to 108 of the protein sequence, named “MLANA”),
DSKVSLQEKNCEPVVPNAPPAYEKLSAEQSPPPYSP (peptide
from MLANA from position 83 to 108 of the protein sequence,
named “phoMLANA,” phosphorylation at S102 in bold), FYLA
MPFATPMEAELARRSLAQDAPPL (peptide from CTAG1A
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or NY-ESO1 from position 90 to 116 of the protein sequence,
named “CTAG1A”).
All peptides were >85% pure and purchased from Pepscan
(Lelystad, The Netherlands). Peptides were resuspended in sterile
pure DMSO prior loading on DCs.
High-Throughput Purification of HLA-I and
HLA-II Complexes
For high-throughput HLA-I and -II immunoaffinity purification,
we used a previously described protocol from our group
(23, 25). We used the 96-well single-use micro-plate with
glass fiber and 10µm polypropylene membranes (ref number:
360063, Seahorse Bioscience, North Billerica, MA). Cell lysis
was performed with PBS containing 0.25% sodium deoxycholate
(Sigma-Aldrich), 0.2mM iodoacetamide (IAA) (Sigma-Aldrich),
1mMEDTA, 1:200 Protease Inhibitors Mixture (Sigma-Aldrich),
1mM Phenylmethylsulfonylfluoride (Roche, Basel, Switzerland),
1% octyl-beta-D glucopyranoside (Sigma-Alrich) at 4◦C for 1 h.
Lysis buffer was added to the cells at a concentration of 1ml per
5e6 cells. Lysates were cleared by centrifugation with a table-top
centrifuge (Eppendorf Centrifuge, Hamburg, Germany) at 4◦C
at 14,200 rpm for 30min. Anti-pan HLA-I (HB95) and HLA-
II (HB145) antibodies cross-linked to protein-A sepharose 4B
beads (Invitrogen, Carlsbad, California) beads were loaded on
their respective plates at a final bead volume of 100 ul. The lysates
were loaded by gravity first through the HLA-I affinity plate
and then through the HLA-II affinity plate at 4◦C. The plates
were washed separately using the Waters Positive Pressure-96
Processor (Waters, Milford, MA) four times with 2ml of 150mM
sodium chloride (NaCl) (Carlo-Erba, Val de Reuil, France) in
20mM Tris-HCl pH 8, four times with 2ml of 400mM NaCl in
20mM Tris-HCl pH 8 and again four times with 2ml of 150mM
NaCl in 20mM Tris-HCl pH 8. Finally, the beads were washed
twice with 2ml of 20mM Tris-HCl pH 8.
Purification of HLA-I and HLA-II Peptides
Two Sep-Pak tC18 100mg Sorbent 96-well plates were required
for the purification and concentration of HLA-I and HLA-II
peptides. Each C18 plate was handled separately. Each affinity
plate was stacked on top of a C18 plate and the HLA complexes
including the peptides were eluted with 500 µl of 1% TFA.
The C18 wells were washed with 2ml of 0.1% TFA. Thereafter,
the HLA peptides were eluted with 500 µl of 32% acetonitrile
(ACN) in 0.1% TFA. The recovered HLA-I and -II peptide
samples were transferred separately into eppendorf tubes, dried
using vacuum centrifugation (Concentrator plus Eppendorf) and
stored at−20◦C.
Proteomics Analysis
Cell pellets of approximately 1e6 cells were resuspended in
lysis buffer composed of 8M Urea (Biochemica, Billingham,
UK) and 50mM ammonium bicarbonate (AMBIC, Sigma-
Aldrich) pH 8. The cell lysates were sonicated in the Bioruptor
instrument (Diagenode, B01020001, Seraing, Belgium) for 15
cycles, each cycle at maximum mA for 30 s at 4◦C. Subsequently,
centrifugation at 20,000 g at 4◦C for 30min separated the
soluble from the insoluble protein fractions. The soluble fraction
was collected and the protein concentration of the lysates
was determined by a Bradford protein assay. Proteins were
reduced with a final concentration of 5mM DTT (Sigma-
Aldrich) at 37◦C for 60min, followed by alkylation with a
final concentration of 15mM iodoacetamide (IAA, Sigma-
Aldrich) at room temperature for 60min in the dark. After the
alkylation step, the digestion was carried out with a mixture
of endoproteinase Lys-C and Trypsin (Trypsin/Lys-c Mix,
Promega, Madison,WI). The first step consists of endoproteinase
Lys-C digestion for 4 h at 37◦C with a protein to enzyme ratio of
50:1 (w/w). Subsequently, the samples were diluted 8 times with
50mM AMBIC to a Urea concentration of 1M. The second step
of digestion was performed with Trypsin overnight at 37◦C with
a substrate to enzyme ratio of 50:1 (w/w). After digestion, the
samples were acidified with formic acid (FA) and desalted on C18
spin columns (Harvard Apparatus, Holliston, MA).
LC-MS/MS Analyses
HLA-I and HLA-II peptide samples were re-suspended in 9 ul
of 0.1% FA and 2/3 of the sample volume were placed in the
UHPLC autosampler. For HLA-I peptidomics, the gradient of
acetonitrile in 0.1% FA consisted (B) of: 0–5min (2–5% B); 5–
65min (5–30% B); 65–70min (30–60% B); 70–75min (60–95%
B); 75–80min (95% B), 80–85min (95–2% B), and 85–90min
(2% B). While for the HLA-II peptides, the gradient slope was
kept the same but with a length of 60min. For proteomics, the
gradient was as such: 0–5min (2–5% B); 5–30min (5–9% B); 30–
180min (9–22% B); 180–230min (22–35% B); 230–250min (35–
60% B); 250–255min (60–95% B); 255–260min (95% B); 260–
265min (95–5% B); and 265–270min (5% B). All samples were
acquired using the nanoflow UHPLC Easy nLC 1,200 (Thermo
Fisher Scientific, LC140) coupled online to a Q Exactive HF or
a HFX Orbitrap mass spectrometers (Thermo Fischer Scientific)
with a nanoelectrospray ion source (Sonation, PRSO-V1, Baden-
Wurttemberg, Germany).We packed the uncoated PicoTip 8µm
tip opening with 75µm i.d. 45 cm long analytical columns with
ReproSil-Pur C18 (1.9 um particles, 120 Å pore size, Dr. Maisch
GmbH, Ammerbuch, Germany). Mounted analytical columns
were kept at 50◦C using a column oven.
For proteomics, data-dependent “top15” method was used.
The mass spectrometer scan range was set to 300 to 1,650 m/z
with a resolution of 60,000 (200 m/z) and the mass spectrometer
scan range was set to 300–800 m/z. For MS/MS, AGC target
values of 1e5 were used with a maximum injection time 25ms
at set resolution of 15,000 (200 m/z). The peptide match option
was disabled. In case of unassigned precursor ion charge states
or a charge state of one, no fragmentation was performed and
the peptide match option was set to “preferred.” The dynamic
exclusion of precursor ions from further selection was set for 20 s.
For immunopeptidomics, data was acquired with data-
dependent “top10” method, which isolates within a 1.2
m/z window the ten most abundant precursor ions and
fragments them by higher-energy collision dissociation (HCD)
at normalized collision energy of 27%. The mass spectrometer
scan range was set to 300 to 1,650 m/z with a resolution of
60,000 (200 m/z) and the AGC target value of 3e6 ions was
set. For MS/MS, AGC target values of 1e5 were used with a
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maximum injection time of 175ms. For HLA-I peptidomics, in
case of assigned precursor ion charge states of four and above, no
fragmentation was performed. For HLA-II peptidomics, in case
of assigned precursor ion charge states of one, and from six and
above, no fragmentation was performed.
For HLA-I experiments with DCs loaded with synthetic
peptides, data was acquired twice; once with data-dependent
“top10” method and once with the same method containing
an inclusion list of precursors (only +1, +2, and +3 charge
states), which comprised 9–12 mer peptides that were predicted
by NetMHCpan4.0 (30) from the long synthetic peptides
sequences (<2% rank). For the predictions, the high-resolution
HLA typing of each donor was used. If predicted peptides
contained methionine (M) in their sequences, then oxidized
forms (+15.99491 Da) of the precursors were added to the
inclusion list. In absence of target masses, the mass spectrometer
was enabled to isolate and fragment other ion precursors.
Database Search
We employed the MaxQuant computational platform version
1.5.5.1 (31) to search the peak lists against the UniProt databases
(Human 42,148 entries, March 2017) and a file containing
247 frequently observed contaminants. Methionine oxidation
(15.99491 Da) was set as a variable modification. For proteomics,
a fixed modification of cysteine carbamidomethylation (57.02146
Da) was used. The second peptide identification option in
Andromeda was enabled. A peptide spectrum match (PSM)
false discovery rate (FDR) of 0.01 and no protein FDR were
set for peptidomics analyses, whereas for proteomic analyses
also a protein FDR of 0.01 was set. For experiments with DCs
loaded with synthetic peptides, a PSM FDR of 0.05 was set and
Serine/Threonine phosphorylation (79.96633 Da) was added as a
variable modification due to the loading of a phosphorylated long
synthetic peptide. The enzyme specificity was set as unspecific for
immunopeptidomics, whereas C-terminal specificity for K and
R, and maximum three miscleavages were chosen for analysis of
proteomics samples. Possible sequence matches were restricted
to 8 to 25 amino acids (a.a.) for immunopeptidomics and
proteomics while to 8 to 30 a.a. for the experiments with DCs
loaded with synthetic peptides. A maximum peptides mass of
4,600 Da for proteomics and 3,000 Da for immunopeptidomics.
The initial allowed mass deviation of the precursor ion was set
to 6 ppm and the maximum fragment mass deviation was set
to 20 ppm. We enabled the “match between runs” option, which
allows matching of identifications across different replicates in a
time window of 0.5min and an initial alignment time window
of 20min between datasets of the same donor (class I and class
II separately). For proteomic analysis, “match between runs”
module was enabled between all samples of the same donor and
label-free quantification (LFQ) was enabled in the MaxQuant
environment (32).
Experimental Design and Statistical
Rationale
A detailed description of the immunopeptidomics class I,
II, and proteomics experimental design, including naming,
RAW MS file names, assignment of replicates, and cell
number used per experiment are, respectively, provided in
Supplementary Tables 2–4. We used the Perseus computational
platform version 1.5.5.3 for all statistical analysis, unless
otherwise indicated (33). For class I and II immunopeptidomics
data, we used the “peptides” MaxQuant output tables and
Peptides matching to reverse and contaminants were filtered out
and intensities were log2 transformed (Supplementary Tables 5,
6, respectively). Binding affinities to the corresponding HLA-
I allotypes expressed in the donors were predicted for all
8–14 mers identified peptides using NetMHCpan4.0. The
threshold for binding was set to rank 2% and the respective
affinity values in nM were extracted. For length distribution
analysis, peptide intensities from technical replicates of the same
donor and cell type were reported as an average value. For
volcano plots analysis, the intensities were normalized using
“width normalization” option in Perseus and missing values
were imputed by drawing random numbers from a Gaussian
distribution with a standard deviation of 20% in comparison
to the standard deviation of measured peptide abundances.
Volcano plots of modulations in the relative intensities of HLA
ligands were generated. Each dot represents a unique HLA
peptide. Log2-fold changes of their abundance are indicated
on the x axis and the corresponding significance levels were
calculated by two-sided unpaired t-test with FDR of 0.01 and
S0 of 1. For proteomic analysis, LFQ intensities of proteins
were retrieved from the “ProteinGroups” MaxQuant output table
(Supplementary Table 7), log2 transformed, and a filter was set
for at least two unique peptides per protein and two valid
values. Missing intensities were imputed as described above and
a volcano plot was generated where the log2-fold changes of
activated vs. unstimulated group are indicated on the x axis
and the corresponding significance levels were calculated by
two-sided unpaired t-test with FDR of 0.01 and S0 of 3.
RESULTS
Molecular Changes Upon Differentiation
and Maturation of Dendritic Cells Modulate
Antigen Presentation Machinery and HLA
Class I and II Presentation
To characterize the biological differences occurring in DCs
upon differentiation and maturation and the possible underlying
changes in properties of HLA ligands naturally presented,
we utilized an experimental pipeline enabling isolation
and purification of sufficient amounts of CD14+ precursor
cells from leukapheresis, apheresis filters, or buffy-coat
samples (Figure 1A and Supplementary Table 1). This was
an essential step for performing a range of experiments
on the same samples, including comparative MS-based
shotgun proteomics and immunopeptidomics analyses in
combination with flow cytometry (summarized in Figure 1A and
Supplementary Tables 2–7). In order to validate differentiation
and maturation of DCs in each of the experimental settings,
we first characterized by flow cytometry known surface makers
such as HLA -I and -II complexes, PDL1, PD2L, CD40,
CD80, CD83, CD86, CD11c. As previously described (34–36),
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FIGURE 1 | Characterization of the repertoire of HLA class I and class II ligands in different cell types with MS-based immunopeptidomics and proteomics
approached. (A) Description of the experimental workflow. Gradient separation was used to isolate PBMCs from healthy donors’ leukapheresis or apheresis samples
(Continued)
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FIGURE 1 | prior to CD14+, CD19+, CD8+, and CD4+ magnetic beads positive selection. Pure CD14+, CD19+, CD8+, and CD4+ cells were either stored, or
activated. In order to study the biogenesis of cross-presentation, immature, and mature DCs were in some experiments also exogenously loaded with synthetic
peptides. Similar amounts of each cell population was subjected to MS-based proteomics, MS-immunopeptidomics, and flow cytometry. (B) Exemplary volcano plots
summarizing unpaired t-test analysis of proteomics expression analysis upon DC differentiation (left) and maturation (right). Proteins located above the lines are
statistically significantly modulated in their level of expression (FDR = 0.01, S0 = 3). (C) HLA-I (upper panel) and HLA-II (lower panel) uniquely identified peptides
identified for CD14+ (blue), immature DC (orange) and mature DC (gray). (D) Proteome remodeling during DC maturation influences the repertoire of the HLA-I
peptidome. Volcano plot (right plot) summarizing unpaired t-test analysis of HLA-I immunopeptidomics analysis upon DC maturation. Peptides located above the lines
are statistically significantly modulated in their level of presentation (FDR = 0.01, S0= 3). The blue dots represent HLA-I peptides which belong to all source proteins
found upregulated upon maturation in the proteomics analysis (red dots, left plot, FDR = 1, S0 = 3).
we confirmed that CD14+ monocytes undergo progressive
upregulation during differentiation and maturation of these
markers (Supplementary Figure 1). We then evaluated global
changes in protein expression and cellular processes by MS-
based shotgun proteomics. Statistical analysis of proteomics
expression values (Figure 1B, unpaired t-test) in an exemplary
experiment revealed marked changes upon DC differentiation
and maturation, where 199 and 765 proteins upregulated and
232 and 21 downregulated, respectively. We further focused on
the expression levels of key proteins involved in HLA class I
and II APPMs. As expected, upregulation of key components of
the APPMs responsible for both HLA-I and HLA-II pathways
was observed upon activation of CD14+ cells to ImmDCs and
upon their differentiation into MaDCs, including CALR, CANX,
TAP1/2, TAPBP, and β2m (Supplementary Figure 2). In each
of the donors, gene ontology (GO) enrichment analyses (37)
showed an enrichment of processes involved in antigen uptake
for ImmDCs (Supplementary Table 8). ImmDCwere stimulated
with LPS and INFγ, and as expected, GO analysis of MaDCs
revealed a strong enrichment related to immune response,
cytokine-mediated signaling pathways, and cellular responses
to INFs, including downstream pathways related to stimulation
of TLR4 and INFγ receptors, that are known to upregulate
components of the APPM (38–40) (Supplementary Table 9).
Next, we characterized with MS-based immunopeptidomics
approach differences in the repertoire of naturally presented
HLA-I and -II immunopeptidomes on different cellular states.
Figure 1C shows enhanced antigen presentation in terms of
number of unique peptides identified in both class I and II
immunopeptidomes of MaDC compared to ImmDC and CD14+
monocytes. We identified on average 3,662, 5,067, and 6,110
HLA-I peptides fromCD14+, ImmDC, andMaDCs, respectively,
extracted from 10 to 17 million cells (Figure 1C, upper panel and
Supplementary Table 5). From the same samples, we identified
on average 667, 2,739, and 3,731 HLA-II peptides, respectively
(Figure 1C, lower panel and Supplementary Table 6). We
further assessed if changes in protein expression during
maturation directly influence HLA class I peptidomic repertoire
with newly synthesized and upregulated proteins being readily
(within 24 h) processed and presented. We observed that source
proteins significantly upregulated in MaDC were significantly
more presented on HLA-I complexes (Figure 1D), supporting a
direct relationship between presented class I immunopeptidomes
and protein expression levels (41) and with the expression of
newly synthesized proteins (42).
Qualitative Changes in the
Immunopeptidome Upon Immune Cell
Stimulation
We then searched for qualitative differences in the HLA class I
and II immunopeptidomes upon activation and differentiation
of DCs that were mediated by changes in the APPM. First,
we assigned identified peptides to the donor’s HLA allotypes
by predicting their binding affinity. We could detect a minor
decrease in the predicted binding affinity of the peptides to their
respective HLA molecules upon activation and differentiation
into the MaDC state (Supplementary Figure 3). Nevertheless,
we found statistically significant differences in the length of
unique peptides presented by MaDC compared to ImmDC and
CD14+ monocytes. That was the case only for HLA allotypes that
have been shown to accommodate longer peptides (Figures 2A,B
and Supplementary Table 10), such as HLA-B∗40:01, HLA-
A∗11:01, HLA-B∗44:03, and HLA-A∗01:01 (43, 44) (p-values for
MaDC vs. ImmDCwere, respectively, 0.0002, 0.0004, 0.0001, and
0.0001, while p-values for MaDC vs. CD14+ were, respectively,
0.0001, 0.0025, 0.0001, and 0.0001). We found little or no
peptide length differences in HLA allotypes that are characterized
with preference for binding peptides of conserved length, such
as HLA-B∗08:01, -B∗51:01, -A∗02:01, and HLA-B∗15:01 (p-
values for MaDC vs. ImmDC were, respectively, 0.04, 0.21,
0.27, and 0.06. While p-values for MaDC vs. CD14+ were,
respectively, 0.3, 0.6, 0.87, and 0.03). To test if this phenomenon
was specific for DCs and/or dependent on TLR4 and INFγ
receptors stimulation, we performed similar analyses on other
immune cells before and after activation, including CD4+ and
CD8+ T cells and CD19+ B cells, purified from the same
donor (Figure 1A). We observed that upon their activation,
similar modulation of the HLA processing and presentation
machineries occurred, subsequently leading to upregulation of
peptide presentation (Supplementary Figure 4). Alike to DCs,
we found in the other tested activated immune cells a statistically
significant difference in the peptide length distribution in case
of HLA allotypes known to accommodate longer peptides
(Figures 2A,B).
Furthermore, we observed similar qualitative changes at
the peptide length distribution for HLA-II peptides in DCs
(Figure 3A). In general, the HLA-II immunopeptidomics data
in CD4+ and CD8+ T cell samples were spares, and we could
not detect substantial upregulation of HLA-II upon maturation
and activation of these T cells (Figure 3B). However, in CD19+
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FIGURE 2 | Length distribution of HLA class I peptides upon differentiation and activation of immune cells. (A) Length distribution across different HLA class I alleles of
naive and activated immune cells. For each donor, MS detected ligands (length 8–14) were separately assigned to each of the HLA alleles with NetMHCpan 4.0 and
their average length was calculated. HLA alleles are displayed from left to right based on their increasing propensity to bind longer peptides. (B) Length distributions
(length 8–14) of unique HLA-I peptides presented in activated vs. unstimulated immune cells of HLA alleles which are expected to accommodate longer peptides.
Average length (L) for each cell type is reported together with the statistical significance (unpaired t-test, p-values).
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FIGURE 3 | Length distribution of HLA class II peptides upon differentiation and activation of immune cells. (A) Upon differentiation and activation of DCs, longer
peptides are presented by HLA-II allotypes. For these comparisons only donors with at least 100 unique peptides were displayed. (B) Overview of unique HLA class II
peptides identified in CD14+, immature and mature DCs, CD8+, CD4+, CD19+ cells either activated, or unstimulated. (C) Length distributions of unique HLA-II
peptides presented in CD19+ either unstimulated or activated with CD40L. Average length (L) for each cell type is reported together with the statistical significance
(unpaired t-test, p-values).
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cells, we observed the same qualitative changes at the HLA-II
peptidomes upon activation (Figure 3C).
Distinct sets of known enzymes, chaperons, and transporters
are responsible for trimming proteins into the final peptide
sequences and for their loading on HLA class I and II complexes
(45, 46). To unveil clues about the proteins that could possibly
be responsible for the generation of longer peptides, we explored
the proteomics data of the investigated cell types. However, no
clear significant changes in the expression of enzymes involved
in processing of HLA class I and II could support a direct link
(Supplementary Figures 5, 6) with the length increase detected
on the HLA-presented peptides.
Study the Biogenesis of Cross-Presented
Exogenously Loaded Antigens
DCs are important vaccine delivery vehicles in cancer
immunotherapy because they can be loaded ex vivo with
vaccine targets and present and cross-present in vivo the
exogenously loaded antigens for priming of naïve T cells (47).
Therefore, we tested if similar differences in peptide length could
be observed for HLA-I and HLA-II peptides that are derived
from the processing and presentation of exogenously loaded
long peptides. We loaded ImmDCs and MaDCs from three
donors with a mixture of equal amounts of seven long peptides
(25–40 mers) from the known cancer associated antigens PMEL,
MAGEA4, MLANA, and CTAG1A (NY-ESO1). The peptides
used for loading were specifically selected as they contained
multiple HLA class I and II peptides already identified by MS
for several HLA restrictions. Importantly, the source proteins
could not be identified as naturally expressed or presented in
the DCs (Figure 4A). In all donors, we identified 16 and 14
presented HLA-I peptides and 82 and 131 HLA-II peptides,
in ImmDC and MaDC cells, respectively (Figures 4B,C,
Supplementary Tables 11, 12). Overall, upon DC maturation,
overlapping cross-presented HLA-I peptides tend to be more
abundant compared to ImmDCs (Figure 4C), and no significant
difference in peptide length was observed between the cell
types. We found that HLA class II peptides derived from the
loaded synthetic peptides were on average longer compared
to HLA-II peptides derived from self-proteins and from fetal
bovine serum (FBS) proteins that were taken up, processed and
presented by the DCs during cell culture (Figure 4D, p-values,
respectively, 0.0001 and 0.05). HLA-II presented ligands derived
from the exogenously loaded synthetic peptides were longer
in MaDC than in ImmDC peptidomics samples (although not
reaching a significant level). Moreover, HLA-II presented ligands
derived from the exogenously loaded synthetic peptides were
more abundant in MaDC than in ImmDC peptidomics samples
(Figure 4E and Supplementary Figure 6).
DISCUSSION
While DCs play a key role in orchestrating highly complex
immune responses against infection agents and tumors, the
presented HLA ligandome in DCs upon their activation and
maturation was largely unexplored, mainly due to the limited
sensitivity and reproducibility of MS-based immunopeptidomics
(24). In this study, we aimed to characterize the repertoire
of naturally presented HLA-I and -II ligands in CD14+
precursors cells, as well as ImmDCs and MaDCs, leveraging our
recently developed improved sample preparation method (23).
Specifically, we searched for properties that would allow, in the
future, improved prediction of immunogenic HLA ligands for
clinical applications, such as for the development of personalized
vaccines using DCs loaded with long peptides (48).
The cellular machineries responsible for the processing and
presentation of source proteins and the presentation of their
degradation products on HLA-I and -II complexes comprise
multiple largely well-characterized enzymes, chaperons, and
transporters. Cellular signaling pathways that are activated
by inflammatory cytokines, such as INFγ, regulate their
expression, and hence, differential expression of key molecules
responsible for antigen processing and presentation is expected
to take place during DCs differentiation and maturation.
In this study we explored the extent such perturbations
affect antigen presentation, by profiling modulation in protein
expression and peptide presentation by shotgun proteomics and
immunopeptidomics. As expected, upon DCs differentiation
and maturation, we observed a marked increase in expression
of multiple proteins involved in antigen presentation and an
increase in cell-surface expression of both HLA-I and -II
complexes, leading to a significant increase in the diversity and
abundance of the presented ligands, where upregulated source
proteins were found to have elevated presentation levels.
We characterized the presented peptides, and while no
striking differences were detected concerning their predicted
binding affinity to the respective HLA allotypes, we found that
on average, HLA-I and HLA-II peptides presented in MaDCs
were slightly, but significantly, longer than those presented
in ImmDCs or in the CD14+ precursor cells. We repeatedly
detected the difference in peptide length in DCs derived from
multiple donors. Similarly, HLA-I and -II peptides presented
in T cells and B cells upon activation were as well longer than
those presented in the inactivated cell states. Here, the study was
limited by the investigation of B cells and T cells from a single
donor. Nevertheless, the results were consistent regardless of the
cell type or the mode of activation. Importantly, the difference
in peptide length was apparent only in HLA-I allotypes that
can accommodate binding of longer peptides, such as in HLA-
B∗40:01, HLA-B∗44:03, andHLA-A∗01:01 (43). Interestingly, our
results are in agreement with a recent paper by Ziegler et al.
where they investigated the effect of HIV-1 infection on changes
in HLA-I-presented peptides by mass spectrometry. They found
a very similar trend of presentation of longer HLA-I peptides on
HLA-B∗40:01 and HLA-B∗27:05 in CD4+ T cells upon activation
or infection, that is HLA allotype dependent (49), where a
more marked length shift was observed for HLA alleles that
can accommodate longer peptides, and it was far less noticeable
or not observed for more “rigid” HLA alleles, such as HLA-
A∗02:01. Importantly, we found that peptides presented on DCs
from loaded long synthetic peptides follow a similar trend. The
difference in peptide length was not observed for the multiple
cross-presented HLA-I peptides we measured by MS, and this
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FIGURE 4 | Dendritic cell exogenous loading. (A) Scheme of synthetic peptides selection for exogenous dendritic cell loading. In-house cancer and dendritic cell
databases, respectively built by measuring protein, HLA class I and class II-bound peptide expressions from tumor tissues/cell lines and CD14+, immature, and
mature dendritic cells. The cancer database was filtered out for proteins which were also found expressed in the dendritic cell database. HLA class I and II-bound
peptides identified by MS were mapped on the remaining list of proteins. Only protein sequences which included multiple HLA class I and II identified peptides
(hotspots’ of antigen presentation) were further selected. Selected “hotspots” sequences (25 to 40 a.a) were further tested with predictions for HLA class I binding of
the most common HLA-A and -B alleles. Seven remaining long peptides were selected for synthesis and exogenous loading to immature and mature dendritic cells.
(B) Identified (FDR 5%) HLA class I and class II-bound FBS-derived (gray) from 3 combined donors, self- (blue for class I and green for class II) and derived from the
exogenously loaded synthetic (orange) peptides from immature and mature dendritic cells. (C) Heat map of log2 intensity values of HLA class I peptides derived from
the exogenously loaded synthetic peptides from immature and mature dendritic cells of 3 donors. (D) Box plot of length distributions of respectively HLA class II from
cell self-proteome, derived from the exogenously loaded peptides and FBS-derived peptides are plotted for immature and mature dendritic cells of 3 donors. Average
length (L) for each cell type is reported together with the statistical significance (unpaired t-test, p-values). (E) Intensities of HLA class II synthetic peptides identified in
immature and mature dendritic cells were summed up for each peptide length and then normalized by the total intensities of identified HLA class II synthetic peptides.
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could be due to the fact that only a limited number of HLA-
I peptides were detected in the loading experiments. However,
HLA-II peptides derived from the processing of the long peptides
were significantly longer in MaDCs, and in activated B cells.
One possible explanation for the presentation or detection
of longer peptides following activation could be related to
the relative higher expression of HLA-I allotypes that can
accommodate binding of longer peptides. Higher expression of
such HLA-I allotypes would lead to a higher absolute number
of longer peptides, yet proportionally, the length distribution of
peptides assigned per HLA-I allotype should remain constant.
For example, if a given HLA-I allele binds preferentially 80% 9,
10% 10, and 10% 11 mers, a two-fold increase in its expression
level will still display the same ratio (80:10:10), unless some
perturbations would enforce a supply of peptide repertoire with
different length characteristics, or if the supply of 9 mer peptides
is the major limiting step. In a recent paper by Komov et al.
IFN induced differential modulation of the HLA-A, B, and
C peptidomes was investigated (50). They elegantly showed
that overexpression of recombinant soluble HLA-A∗02:01,
introduced to compete for peptides with the endogenous
membrane-bound HLA-A∗02:01, did not alter the expression
level or features of the presented peptidome of the membrane-
bound HLA-A∗02:01. Their results indicate that a surplus supply
of peptides is available inside the Endoplasmic reticulum for
loading onto the HLA-I peptide-receptive molecules, and that
the availability of empty HLA molecules limits surface HLA-
I expression. Therefore, the differential presentation of longer
peptides in our experiments could be due to higher expression
level of HLA-I allotypes, that can accommodate binding of
relatively longer peptides, only if the 9 mer peptides supply is a
major limiting factor.
Multiple cellular factors could be responsible for production
of longer peptides, and the leading suspects are the proteases
involved with peptide trimming in the endoplasmic reticulum or
in the endosome-lysosome compartments, or proteins involved
in the antigen-loading complex, which facilitate loading of
peptides on particular HLA molecules. Activation of cells might
induce cellular stress, which could consequently affect the
APPM. We could not find consistent evidence to correlate
differences in expression level of proteins involved in the
APPMs to conclusively pinpoint the proteins responsible for the
presentation of longer peptides, and in addition, their activity
is likely to be regulated by other means than expression levels.
Hence, the molecular mechanism leading to the presentation
of longer peptides upon cellular activation and maturation
is still unknown, and more detailed research is required for
resolving this.
The similarity between the self-peptidome presented on
cancer cells and on autologous antigen presenting cells is still
largely unknown. Hence, our ability to select cancer-specific
antigens for DC-based vaccines (e.g., synthetic long peptides
and RNA vaccines), that are naturally presented with identical
epitopes on both loaded DCs and on the autologous tumor cells
in vivo, is limited. Overall, the notion is that antigen presentation
is similar in both cell types. Here we provide first evidence that
the presentation of HLA ligands in DCs is a dynamic process
and we report that longer peptides are presented on DCs upon
maturation, in an HLA-dependent manner. Ziegler et al. recently
demonstrated that HIV-1 viral infection of stimulated CD4+ T-
cells induced a significant shift toward presentation of longer
HLA-I peptides (49) and several years ago it has been shown
by Yaciuk et al. that epitopes as long as 20 amino acids were
eluted from HLA-A∗11:01 HIV-1 infected CD4+ T cells (51).
In addition, McMurtrey et al. showed that in cells infected with
Toxoplasma gondii, HLA-I peptides derived from the pathogen
were longer compared to the baseline ligandome derived from
the host proteome (52). Furthermore, highly immunogenic
bulged long HLA-I binding peptides, for example from HIV,
cytomegalovirus and EBV, have been shown to interact strongly
with TCRs (51, 53–57). In a previous study we showed that tumor
cells in the presence of inflammatory cytokine, like INFγ, present
longer HLA-I peptides (23), suggesting a common mechanism
enabling presentation of similar epitopes in both the antigen
presenting cells and the inflamed diseased cells, that are distinctly
different (by length) than ubiquitous “healthy” self-peptidome.
We hypothesize that in the tumor microenvironment, activated
DCs will efficiently process and present a larger fraction of longer
peptides, for example from tumor antigens released from dying
tumor cells, and hence, will prime T cells also against these
longer epitopes, that will be also presented directly on the tumor
cells in the inflamedmicroenvironment (49, 51–57). We envision
that including such features in immunogenicity prediction tools
would improve their efficacy and the development of cancer
vaccines and T cell based immunotherapies. More research
however, is required to further decipher the cellular mechanisms
that are directly involved in shaping the immunopeptidome in
the tumor microenvironment as well as under chronic exposure
to inflammatory signals.
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Supplementary Figure 1 | Representative FACS data of DC maturation and T
cell activation marker expression. (A) Upon maturation with IFNg and LPS, HLA
expression is upregulated, as well as a number of other markers. Cells were gated
as following: Upon dead, size, and doublet exclusion, DCs were identified as
CD11c+ and CD14−. (B) PMA/Ionomycin stimulation of T cells from the same
donor as in A, results in upregulation of various activation markers. As with DCs,
DAPI+ dead cells, and doublets were excluded and CD8+ and CD4+ were
subsequently selected.
Supplementary Figure 2 | Overview of donor D1 HLA class I presentation
pathway. Log2 fold change of protein LFQs values between immature and mature
DCs of proteins involved in HLA- I antigen presentation pathway in donor D1.
Supplementary Figure 3 | Overview of donor D1 HLA class I presentation
pathway. Box plot of affinities (nM) predicted with NetMHCpan 4.0 of CD14+,
immature and mature dendritic cells. Distribution of predicted affinities for each cell
type is reported together with the statistical significance (unpaired t-test,
p-values).
Supplementary Figure 4 | Overview of donor D4 HLA class I presentation in all
immune cell types activated or unstimulated. (A) Log2 fold change of protein
LFQs between activated and unstimulated immune cells of proteins involved in
HLA-I antigen presentation pathway in donor D4. (B) number of unique HLA-I
peptides identified in CD14+, immature and mature DCs, CD8+, CD4+, CD19+
cells either activated, or unstimulated in donor D4.
Supplementary Figure 5 | Proteomics expression of processing enzymes
possibly involved in HLA- I pathway. (A) Log2 fold change of protein LFQs
between mature and immature DCs of enzymes possibly involved in HLA-I antigen
processing pathway. (B) Log2 fold change of protein LFQs between activated and
unstimulated immune cells from the same donor (D4) of enzymes possibly
involved in HLA- I antigen processing pathway.
Supplementary Figure 6 | Proteomics expression of processing enzymes
possibly involved in HLA class II pathway. Log2 fold change of protein LFQs
between mature and immature dendritic cells of enzymes possibly involved in HLA
class II antigen processing pathway.
Supplementary Figure 7 | Log2 intensity values of HLA-II peptides identified in
immature and mature DCs from 3 donors derived from the exogenously loaded
synthetic peptides PMEL 155-195 and PMEL 201-234.
Supplementary Table 1 | Donors and experimental details. For each donor used,
specimen type, HLA class I typing, immune cell type extracted, and type of
experiments executed per cell type are described.
Supplementary Table 2 | Experimental design HLA class I immunopeptidomics.
For each donor’s HLA class I experiments, cell types, experiment type, replicate
type, amount of cell used, and mass spectrometry RAW file names are listed.
Supplementary Table 3 | Experimental design HLA class II immunopeptidomics.
For each donor’s HLA class II experiments, cell types, experiment type, replicate
type, amount of cell used, and mass spectrometry RAW file names are listed.
Supplementary Table 4 | Experimental design proteomics. For each donor’s
proteomics experiments, cell types, experiment type, replicate type, amount of cell
used, and mass spectrometry RAW file names are listed.
Supplementary Table 5 | MaxQuant Peptide output table of Donor 1 to 4 HLA
class I identified peptides.
Supplementary Table 6 | MaxQuant Peptide output table of Donor 1 to 4 HLA
class II identified peptides.
Supplementary Table 7 | MaxQuant Protein group output table of Donor 1 to 4
proteomics experiments.
Supplementary Table 8 | GO enrichment of molecular functions upon DC
differentiation. GO enrichment of molecular functions was calculated by String
(version 10.5). For this analysis, from each donor were used proteins found to be
significantly upregulated (FDR = 1%, S0 = 3) upon monocyte differentiation to
immature dendritic cells in proteomics analysis. The top 20 enriched functions are
reported.
Supplementary Table 9 | GO enrichment of molecular functions upon DC
maturation. GO enrichment of molecular functions was calculated with String
(version 10.5). For this analysis, from each donor were used proteins found to be
significantly upregulated (FDR = 1%, S0 = 3) upon maturation of immature
dendritic cells in proteomics analysis. The top 20 enriched functions are reported.
Supplementary Table 10 | Average peptide length across different HLA class I
alleles of naive and activated immune cells (related to Figure 2A). For each donor,
MS detected ligands (length 8–14) were separately assigned to each of the HLA
alleles with NetMHCpan 4.0 and their average length was calculated.
Supplementary Table 11 | HLA class I peptides from synthetic peptides from
Donor 5 to 7.
Supplementary Table 12 | HLA class II peptides from synthetic peptides from
Donor 5 to 7.
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